Filing Details
- Accession Number:
- 0001209191-20-031895
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-26 07:03:38
- Reporting Period:
- 2020-05-22
- Accepted Time:
- 2020-05-26 07:03:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1681682 | Endra Life Sciences Inc. | NDRA | () | CA |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1083544 | Anthony Digiandomenico | C/O Endra Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor MI 48105 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-05-22 | 10,000 | $0.78 | 252,083 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.74 to $0.81, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- Includes unvested restricted stock units.